Ad hoc announcement pursuant 5 WpHG: Carl Zei Meditec AG achieves revenue grow of approximately 9% in first half year 05/6

JENA/Germany, 04.04.2016.

Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of approximately EUR 542 million in the first half year 2015/16, based on preliminary data. This corresponds to a growth rate of around 9% over the previous year's value of EUR 498 million. Currency-adjusted revenue growth amounted to approximately 5.5%.

From today's point of view, the company expects operating profit (EBIT) and earnings per share (EPS) to also rise above the previous year's period.

The half year report 2015/16 will be published on 11 May 2016.

Jann Gerrit Ohlendorf

Director Corporate Communications

Carl Zeiss Meditec AG

Phone: +49 3641 220-331

Fax: +49 3641 220-332

press.meditec@zeiss.com

Sebastian Frericks

Director Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

investors.meditec@zeiss.com

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of ZEISS is rounded off by promising future technologies such as intraoperative radiation therapy. With approx. 2,900 employees worldwide, the Group generated revenue of 1,040 million in fiscal year 2014/2015 (to 30 September).

The Group's head office is in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Companys presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more information visit our website at:

www.zeiss.com/med

Number: 0033-2016-ENG OP

Number of Words: 99

Number of Characters: 620

LINK:	http://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/CDF4...
	See more stories from zeiss

Most recent headlines